TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01138488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
Study: NCT00498589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: 25 mg per week IM or SC during 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one intramuscular injection per week
Study: NCT01458418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
Study: NCT01331070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cerebral fMRI
Description: the central breathing control with cerebral fMRI in COPD patients
Study: NCT04885582

Intervention type: OTHER
Intervention: HLA antigen results
Description: HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.

Intervention type: OTHER
Intervention: HLA antigen results
Description: HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
Study: NCT02687724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Description: GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab (GLM)
Description: GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
Study: NCT02295124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
Study: NCT03728647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimedia health education
Description: The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular health education
Description: The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
Study: NCT02270385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PU prevention programme
Description: The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual PU prevention care
Description: Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
Study: NCT00926146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCMIT
Description: Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCMIT
Description: Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
Study: NCT04675034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Dose A: MEDI7352 Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Dose B: MEDI7352 Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Dose C: MEDI7352 Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Dose D: MEDI7352 Q2W

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match MEDI7352 Q2W
Study: NCT00895817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swallowed fluticasone
Description: 440 µg twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40 mg once daily for 8 weeks
Study: NCT03176823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellAegis Technologies autoRIC device
Description: The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Best Practice Management of Traumatic Brain Injury
Description: Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Management of Traumatic Brain Injury
Description: Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
Study: NCT01855919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02989701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
Study: NCT01458418

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Montelukast
Description: Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
Study: NCT02140268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Description: Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
Study: NCT01331070

Intervention type: OTHER
Group type: OTHER
Intervention: cerebral fMRI
Description: the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
Study: NCT02140268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 and Midazolam
Description: On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
Study: NCT03517228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAUM device
Description: The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
Study: NCT03388190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOX
Description: FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
Study: NCT02357147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amatuximab
Description: Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT02839213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butyl bromide
Study: NCT00213265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Description: For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 7-valent Conjugate Vaccine
Description: Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose
Study: NCT03083301

Intervention type: OTHER
Intervention: Medical Files data extraction
Description: Medical Files data extraction
Study: NCT03832751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy before and after NB-UVB phototherapy
Description: skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
Study: NCT02839213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study: NCT01583699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscope
Description: Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
Study: NCT00405925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trizivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine,lamivudine,abacavir
Description: zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
Study: NCT01070849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational booklet
Description: Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRENA
Description: Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RÜCKGEWINN
Description: For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
Study: NCT01527331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: cpr video decision aid
Study: NCT01336647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A - Low-Dose Ha44 0.37% w/w
Description: Low Dose Ha44 Gel applied to scalp and hair for 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B - High Dose Ha44 Gel 0.74% w/w
Description: High Dose Ha44 Gel applied to scalp and hair for 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group C - Placebo
Description: Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
Study: NCT00626067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully functional monitoring device
Description: Pt received fully functional monitoring dispenser for use with their Travatan eye drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially functional monitoring device
Description: Patient received a particually functional Travatan Compliance Monitoring Dispenser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-functional monitoring device
Description: Patient received a non functioning Travatan Compliance Monitoring Dispenser
Study: NCT04282018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-10188
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-10188
Description: Administered as specified in the treatment arm
Study: NCT00399061

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systane, Optive, Restasis
Description: Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
Study: NCT04258592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)MFBG
Description: One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Adult patients will undergo a dynamic PET scan for the first 30 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
Study: NCT06515847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End of Life Nursing Care Plan
Description: the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
Study: NCT04282018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-10188
Description: Administered as specified in the treatment arm
Study: NCT04258592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood samples
Description: Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, in patients undergoing a dynamic PET scan venous blood samples will be obtained for metabolite analysis and activity measurements at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min and 120 ± 60 min in adult participants; 5 ± 2 min, 10 ± 5 min, 30 ± 15 min, 50 ± 25 min, 90 ± 30 min in minor participants).
Study: NCT03832751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy before and after NB-UVB phototherapy
Description: skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
Study: NCT03334604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Description: Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in taste, smell and color to the multispecies probiotic.
Study: NCT01486342

Intervention type: RADIATION
Intervention: PET-CT scan
Description: PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames.
Study: NCT01732276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT04282018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm
Study: NCT02287428

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiotherapy (approximately 60 Gy over 6 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiotherapy (approximately 60 Gy over 6 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiotherapy (approximately 60 Gy over 6 weeks)
Study: NCT02357147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT02287428

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiotherapy (approximately 60 Gy over 6 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiotherapy (approximately 60 Gy over 6 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized NeoAntigen Peptides
Description: NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.